CRTX - CRTX STOCK NEWS

Cortexyme, Inc. (Nasdaq: CRTX) announced the successful completion of its Phase 1 clinical trial of COR588, a lysine gingipain inhibitor aimed at treating Alzheimer’s disease. The trial demonstrated that COR588 was well-tolerated across all doses (25 mg to 200 mg for SAD, 50 mg to 200 mg for MAD) with no serious adverse events and a favorable pharmacokinetic profile. High central nervous system penetration was confirmed after 10 days of administration. The company plans to announce further development strategies on August 1, 2022.

Cortexyme, Inc. (NASDAQ: CRTX) announced promising preclinical results for its 3CLpro inhibitor, COR803, targeting SARS-CoV-2 infections, including COVID-19. In vivo studies demonstrated a significant reduction in viral load and improved lung pathology after oral treatment. COR803 features high potency with an EC90 of 12 nM and offers broad-spectrum activity against coronaviruses. The company is in the IND-enabling phase for COR803 and is pursuing partnerships to support its development.

Cortexyme, Inc. (Nasdaq: CRTX) has appointed June Bray, a veteran with over four decades in pharmaceutical development, to its Board of Directors. This addition aims to enhance the company's strategic direction in advancing clinical-stage therapeutics and expanding its pipeline. Ms. Bray's previous roles include Senior VP at Allergan, where she led successful NDA approvals. Her extensive experience is expected to contribute significantly to Cortexyme's regulatory strategy and new business opportunities in rare and degenerative diseases.

Cortexyme, Inc. (Nasdaq: CRTX) announced the appointment of Dr. Philip S. Low to its Board of Directors, enhancing its leadership team. Dr. Low, a prominent figure in targeted drug discovery, joins alongside Dr. Marwan Sabbagh, a neurologist specializing in Alzheimer's care. This change coincides with Cortexyme's acquisition of Novosteo, aiming to strengthen its scientific capabilities. Dr. Low brings over 30 years of experience and numerous accolades, which is expected to drive innovation in treating degenerative diseases.

Cortexyme, Inc. (Nasdaq: CRTX) has successfully completed its acquisition of Novosteo, a biotech firm specializing in therapeutics for rare skeletal diseases. Following the acquisition, Novosteo shareholders will own approximately 15.5% of the combined company. Cortexyme appointed Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO. The company plans to rebrand as Quince Therapeutics, Inc. Additionally, Cortexyme granted stock options for 3,744,255 shares under its inducement plan, with vesting scheduled over four years.

Cortexyme, Inc. (Nasdaq: CRTX) will participate in The 4th International Conference on Porphyromonas gingivalis from May 15-17, 2022 in Louisville, Kentucky. Dr. Mark Ryder will present findings from the GAIN Trial, focusing on the role of P. gingivalis in oral and systemic diseases, particularly Alzheimer's. The presentation titled, 'A Role for P. gingivalis in Alzheimer’s Disease: Evidence from the GAIN Study,' aims to shed light on its connection to neurodegeneration. Access to the presentation will be available on Cortexyme's website on May 16, 2022.

Cortexyme, Inc. (Nasdaq: CRTX) announced plans to acquire Novosteo, a biotech firm focused on treatments for rare skeletal diseases. The acquisition, approved by both boards, will give Novosteo shareholders approximately 15.5% of the combined entity, expected to close in 30 days. This move enhances Cortexyme's product pipeline with NOV004, a precision bone growth molecule aimed at treating conditions like osteogenesis imperfecta. Leadership changes include Dr. Dirk Thye as CEO. The company plans to rebrand as Quince Therapeutics and trade under the symbol QNCX.

Cortexyme, Inc. (Nasdaq: CRTX) presented new biomarker and target engagement data from its GAIN Trial at the AD/PD 2022 Conference. Key findings indicate that lysine gingipain inhibition by atuzaginstat may slow cognitive decline by 30% to 50% in patients with high P. gingivalis levels. The trial also shows beneficial trends in traditional biomarkers like phospho-tau 181 and brain volumetric measures, suggesting a correlation with improved clinical outcomes. These insights enhance understanding of the role of P. gingivalis in Alzheimer’s disease and support further development of Cortexyme's gingipain inhibitor pipeline.

Cortexyme, Inc. (Nasdaq: CRTX) has appointed Dr. Marwan Noel Sabbagh, a prominent neurologist in Alzheimer’s and dementia care, to its Board of Directors. His expertise is expected to enhance the company’s clinical development efforts and proprietary pipeline aimed at treating degenerative diseases. Dr. Sabbagh has over 30 years of experience and has contributed to numerous Alzheimer's research initiatives. Cortexyme focuses on innovative therapeutic approaches targeting the infectious pathogen P. gingivalis, associated with Alzheimer’s disease, and aims to improve patient outcomes.